On Monday, Verve Therapeutics Inc (NASDAQ: VERV) opened higher 4.07% from the last session, before settling in for the closing price of $6.64. Price fluctuations for VERV have ranged from $6.42 to $21.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 126.44% over the last five years. Company’s average yearly earnings per share was noted 8.02% at the time writing. With a float of $54.79 million, this company’s outstanding shares have now reached $81.97 million.
The firm has a total of 255 workers. Let’s measure their productivity.
Verve Therapeutics Inc (VERV) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Verve Therapeutics Inc is 30.25%, while institutional ownership is 72.32%. The most recent insider transaction that took place on Apr 02 ’24, was worth 12,475. In this transaction Chief Administrative Officer of this company sold 1,514 shares at a rate of $8.24, taking the stock ownership to the 8,659 shares. Before that another transaction happened on Nov 29 ’23, when Company’s Chief Financial Officer sold 554 for $11.45, making the entire transaction worth $6,343. This insider now owns 4,060 shares in total.
Verve Therapeutics Inc (VERV) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 8.02% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Check out the current performance indicators for Verve Therapeutics Inc (VERV). In the past quarter, the stock posted a quick ratio of 17.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 46.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.13, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -3.10 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Analysing the last 5-days average volume posted by the [Verve Therapeutics Inc, VERV], we can find that recorded value of 1.02 million was lower than the volume posted last year of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 13.30%. Additionally, its Average True Range was 0.76.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 3.79%, which indicates a significant decrease from 17.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.10% in the past 14 days, which was lower than the 98.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.14, while its 200-day Moving Average is $13.38. Now, the first resistance to watch is $7.14. This is followed by the second major resistance level at $7.37. The third major resistance level sits at $7.71. If the price goes on to break the first support level at $6.57, it is likely to go to the next support level at $6.23. Now, if the price goes above the second support level, the third support stands at $6.00.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
There are currently 83,619K shares outstanding in the company with a market cap of 542.78 million. Presently, the company’s annual sales total 11,760 K according to its annual income of -200,070 K. Last quarter, the company’s sales amounted to 5,140 K and its income totaled -48,350 K.
